Patents Assigned to Galmed Research and Development Ltd.
  • Patent number: 11571431
    Abstract: The present invention relates to salts of arachidyl amido cholanoic acid (Aramchol), pharmaceutical compositions comprising Aramchol salts, methods for their preparation, and methods of use thereof in medical treatment.
    Type: Grant
    Filed: October 24, 2021
    Date of Patent: February 7, 2023
    Assignee: Galmed Research and Development Ltd
    Inventors: Allen Baharaff, Idit Eshkar-Oren
  • Patent number: 11197870
    Abstract: The invention relates to the treatment and reduction of fibrosis, specifically hepatic fibrosis. More specifically, embodiments of the invention provide compositions and methods useful for the treatment and inhibition of hepato-fibrotic conditions associated with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), employing the use of 3?-arachidylamido-7?,12?-dihydroxy-5?-cholan-24-oic acid (Aramchol) or a pharmaceutically acceptable salt thereof. In other embodiments, the treatment and inhibition of hepato-fibrotic conditions caused by contact with hepatotoxic chemical substances or by mechanical obstruction is contemplated.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: December 14, 2021
    Assignee: Galmed Research and Development Ltd
    Inventors: Liat Hayardeny-Nissimov, Tali Gorfine, Allen Baharaff, Jose M. Mato de la Paz
  • Patent number: 11166964
    Abstract: The present invention is directed to the modulation of gut microbiota. Specifically, the invention relates to pharmaceutical compositions for use in restoring gastrointestinal homeostasis and in alleviating gastrointestinal disorders and other conditions associated with imbalance of gut flora. More specifically, the invention relates to the use of compositions comprising a therapeutically effective amount of a fatty acid bile acid conjugate (FABAC).
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: November 9, 2021
    Assignee: Galmed Research and Development Ltd
    Inventors: Maya Halpern, Allen Baharaff
  • Publication number: 20210169901
    Abstract: The present invention is directed to the modulation of gut microbiota. Specifically, the invention relates to pharmaceutical compositions for use in restoring gastrointestinal homeostasis and in alleviating gastrointestinal disorders and other conditions associated with imbalance of gut flora. More specifically, the invention relates to the use of compositions comprising a therapeutically effective amount of a fatty acid bile acid conjugate (FABAC).
    Type: Application
    Filed: January 19, 2017
    Publication date: June 10, 2021
    Applicant: Galmed Research and Development Ltd.
    Inventors: Maya Halpern, Allen Baharaff
  • Patent number: 10849911
    Abstract: The present invention relates to salts of arachidyl amido cholanoic acid (Aramchol), pharmaceutical compositions comprising Aramchol salts, methods for their preparation, and methods of use thereof in medical treatment.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: December 1, 2020
    Assignee: Galmed Research and Development Ltd.
    Inventors: Allen Baharaff, Idit Eshkar-Oren
  • Publication number: 20190328751
    Abstract: The present invention relates to salts of arachidyl amido cholanoic acid (Aramchol), pharmaceutical compositions comprising Aramchol salts, methods for their preparation, and methods of use thereof in medical treatment.
    Type: Application
    Filed: June 8, 2016
    Publication date: October 31, 2019
    Applicant: Galmed Research and Development Ltd.
    Inventors: Allen Baharaff, Idit Eshkar-Oren
  • Publication number: 20180125862
    Abstract: The invention relates to the treatment and reduction of fibrosis, specifically hepatic fibrosis. More specifically, embodiments of the invention provide compositions and methods useful for the treatment and inhibition of hepato-fibrotic conditions associated with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), employing the use of 3?-arachidylamido-7?,12?-dihydroxy-5?-cholan-24-oic acid (Aramchol) or a pharmaceutically acceptable salt thereof. In other embodiments, the treatment and inhibition of hepato-fibrotic conditions caused by contact with hepatotoxic chemical substances or by mechanical obstruction is contemplated.
    Type: Application
    Filed: October 20, 2017
    Publication date: May 10, 2018
    Applicant: Galmed Research and Development Ltd.
    Inventors: Liat Hayardeny-Nissimov, Tali Gorfine, Allen Baharaff, Jose M. Mato de la Paz
  • Patent number: 8975246
    Abstract: A method for treating a disease or disorder associated with altered glucose metabolism or insulin action in a subject in need thereof. The method includes administering to the subject a BAFAC (bile acid or bile salt fatty acid conjugate) of general formula II: W-X-G in which G is a bile acid or bile salt radical, which is optionally conjugated in position 24 with a suitable amino acid, W stands for one or two fatty acid radicals, each having from 14-22 carbon atoms, and X is a suitable bonding member or a direct C?C bond between G and each W, said suitable bonding member being selected from the group consisting of NH, O, P and S. The disease or disorder associated with altered glucose metabolism is selected from the group consisting of hyperglycemia, diabetes, insulin resistance and obesity.
    Type: Grant
    Filed: February 6, 2012
    Date of Patent: March 10, 2015
    Assignee: Galmed Research and Development Ltd.
    Inventor: Beatrice Gilat